Hikal Ltd
Hikal Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Pharma business expected to grow at approximately 12% to 15% revenue growth in FY '26, driven by increased CDMO inquiries and development projects. Pharma business expected to grow 12% to 15% revenue in FY '26 with corresponding EBIT margin improvement (Page 4, 7, 12).
From Hikal Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Pharma business expected to grow at approximately 12% to 15% revenue growth in FY '26, driven by increased CDMO inquiries and development projects.
- Crop Protection business anticipated to remain flattish in FY '26 with growth resuming from FY '27 onwards as market stabilizes and new product launches ramp up.
- Animal Health segment showing strong momentum with a healthy pipeline and increasing regulatory oversight, signaling future growth potential.
- New high-potency chemistry laboratory coming online by Q3 FY '26, expected to increase participation in high-value RFQs and add to growth.
- CDMO segment managing a robust pipeline of 12 to 15 new opportunities, supporting long-term growth and diversification.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Hikal Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Hikal Limited plans capex of approximately INR 200 crores each year for FY '26 and FY '27.
- Investment is focused on capacity, talent, and technology to support scale readiness and enhance competitive edge.
- A new high-potency chemistry laboratory (mini pilot plant) is being commissioned by Q3 FY '26 to enable participation in high-potency anticancer drug projects and early clinical trial material production.
- Continued investments are being made in R&D, allocating 4-5% of revenue toward innovation.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hikal Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The Crop Protection CDMO division is managing a robust pipeline of 8 active projects with existing and new strategic customers.
- The Animal Health segment has received validation for 8 products and is working with multiple innovators.
- The Pharma business has around 12 to 15 products in advanced stages of development and commercialization, up from 6 to 9 the previous year (more than 50% increase).
- The new high-potent chemistry lab expected to be operational by Q3 FY '26 will increase participation in RFQs, potentially boosting project inflow by 30-40% or more.
2 more points management made on order book & pipeline
Hikal Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹519 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hikal's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmova Ltd (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare Ltd (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals Ltd (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Frequently Asked Questions
What were Hikal Ltd Q4 FY25 results?
Pharma business expected to grow at approximately 12% to 15% revenue growth in FY '26, driven by increased CDMO inquiries and development projects. Pharma business expected to grow 12% to 15% revenue in FY '26 with corresponding EBIT margin improvement (Page 4, 7, 12).
What is Hikal Ltd share price analysis?
Hikal Ltd currently shows a neutral. The stock trades at a P/E of 63.4 with a market cap of ₹2,688 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hikal Ltd planning capital expenditure?
Hikal Limited plans capex of approximately INR 200 crores each year for FY '26 and FY '27.
Keep Hikal Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.